[London, UK – March 10, 2010]
Recognizing Excellence in Health Care
The annual BMJ Group Awards recognises individuals, organisations, and initiatives that have demonstrated outstanding and measurable contributions to health care. An article on malaria published in The Lancet received the Award of Research Paper of the Year.Among the authors are a DNDi Senior Project Manager (Isabela Ribeiro), a DNDi Board member (Prof. Abul Faiz), WHO/TDR researchers, and investigators from several countries.
The awarded article is the following:
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial by Gomes M.F, Faiz M.A, Gyapong J.O, Warsame M, Agbenyega T, Babiker A, Baiden F, Yunus E.B, Binka F, Clerk C, Folb P, Hassan R, Hossain M.A, Kimbute O, Kitua A, Krishna S, Makasi C, Mensah N, Mrango Z, Olliaro P, Peto R, Peto T.J, Rahman M.R, Ribeiro I, Samad R, White N.J, for the Study 13 Research Group.
The article has been made available online in December 2008 and in print in 2009 in The Lancet.
Click here to access the article
More info about BMJ Group Awards: http://groupawards.bmj.com/
WHO/TDR News about the Award: http://apps.who.int/tdr/svc/news-events/news/rectal-artesunate-bmj-award
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit product development partnership working to research and develop new and improved treatments for neglected disease, in particular human African trypanosomiasis, leishmaniasis, Chagas disease, and malaria. With the objective to address unmet patient needs for these diseases, DNDi was established in 2003 by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, the Pasteur Institute, and Médecins sans Frontières (MSF). WHO/TDR acts as a permanent observer. Working in partnership with industry and academia, DNDi has the largest ever R&D portfolio for kinetoplastid diseases. Since 2007, DNDi has delivered three products, two fixed-dose anti-malarials “ASAQ” and “ASMQ”, and a combination treatment for the advanced stage of sleeping sickness “NECT” (nifurtimox-eflornithine combination therapy).
For more information: www.dndi.org
Eva van Beek, Communications Manager
Mob: +41 (0)79 309 39 10 / T: +41 (0)22 906 92 50